title: [Factors associated with the poor coverage of Intermittent Preventive Treatment in pregnant women in the Pobè-Adja-Ouèrè-Kétou health zone in Benin].
abstract: World Health Organization estimates indicate 216 million malaria episodes in 2010, including 81% in the African region. One of the recommended means of prevention in pregnant women is intermittent preventive treatment, until 2012, two doses of sulfadoxine/pyrimethamine or three doesfor a woman living with HIV In the Pobè-Adja-Ouèrè-Kétou health zone of Benin, coverage ofintermittent preventive treatment remains low (49% against a forecast of 80%) several years after implementation of this strategy. We conducted a cross-sectional study in June and July 2012 to identify factors associated with low intermittent preventive treatment coverage in this area. A total of 339 women were interviewed and 48% ofthem received less than two doses of sulfadoxine pyrimethamine during their prenatal consultations. The variables associated with low intermittent preventive treatment coverage were low antenatal care coverage (p < 0.001) and a prenatal consultation in the private sector (p = 0.039). In the light of our results, actions must be taken by this health zone to encourage women to complete the four visits during pregnancy.
authors.forename: Justin
authors.initials: J
authors.lastname: Tiendrebéogo
authors.forename: Maxime
authors.initials: M
authors.lastname: Koiné Drabo
authors.forename: Jacques
authors.initials: J
authors.lastname: Saizonou
authors.forename: Crespin Théodore
authors.initials: CT
authors.lastname: Soglohoun
authors.forename: Noël Moussiliou
authors.initials: NM
authors.lastname: Paraiso
authors.forename: Ali
authors.initials: A
authors.lastname: Sié
authors.forename: Laurent Tinoaga
authors.initials: LT
authors.lastname: Ouédraogo
authors.forename: Michel
authors.initials: M
authors.lastname: Makoutodé
mesh_terms: D000328:Adult; D000962:Antimalarials / Q000627:therapeutic use*; D001541:Benin / Q000453:epidemiology; D003430:Cross-Sectional Studies; D004338:Drug Combinations; D005260:Female; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D008288:Malaria / Q000453:epidemiology / Q000517:prevention & control*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control; D011295:Prenatal Care / Q000379:methods / Q000706:statistics & numerical data; D011315:Preventive Medicine / Q000592:standards; D011739:Pyrimethamine / Q000627:therapeutic use; D012959:Socioeconomic Factors; D013413:Sulfadoxine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000962:Antimalarials; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D011739:Pyrimethamine